Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2020

01-12-2020 | Breast Cancer | Research

Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors

Authors: Winnie Yeo, Elizabeth Pang, Giok S. Liem, Joyce J. S. Suen, Rita Y. W. Ng, Christopher C. H. Yip, Leung Li, Claudia H. W. Yip, Frankie K. F. Mo

Published in: Health and Quality of Life Outcomes | Issue 1/2020

Login to get access

Abstract

Introductions

For young premenopausal breast cancer patients, adjuvant chemotherapy may cause menstrual disruptions and premature menopause, which may in turn impair their quality of life (QoL). In this study among young breast cancer survivors who have undergone adjuvant chemotherapy, the objectives were to assess post-treatment menopausal symptoms and their associated factors, and to correlate these symptoms with breast cancer-specific QoL.

Methods

The study population included premenopausal young Chinese women with early-stage breast cancer who had undergone adjuvant chemotherapy between 3 and 10 years prior to enrolling into this study. At study entry, patients’ characteristics and clinical features were collected; each patient had detail menstrual history collected and each filled in MENQOL and FACT-B + 4 questionnaires.

Results

Two hundred eighty eligible patients were recruited. For adjuvant chemotherapy, 92% received anthracyclines and 28% received taxanes; 76% received adjuvant tamoxifen. At a median of 5.0 years from initial cancer diagnosis, 49 and 11% had become post- and peri-menopausal respectively. MENQOL at study entry revealed that physical domain score was worse in overweight/obese patients (mean scores for underweight/normal vs overweight/obese: 2.65 vs 2.97, p = 0.0162). Vasomotor domain score was worse in those who received taxanes or tamoxifen (taxane vs non-taxane: 2.91 vs. 2.35, p = 0.0140; tamoxifen vs no tamoxifen: 2.75 vs. 2.34, p = 0.0479). Sexual domain score was worse among those who had become peri/post-menopausal (peri/postmenopausal vs premenopausal: 2.82 vs. 2.29, p = 0.0229). On the other hand, patients who utilized traditional Chinese medicine had significantly worse scores for vasomotor, psychosocial and physical domains. Further, there was a significant association between MENQOL scores and FACT-B + 4 scores; less severe symptoms in the MENQOL domains were associated with better QoL scores in FACT-B + 4 physical, functional, psychosocial and emotional well-being, Breast Cancer Subscale, Arm Subscale and FACT-B total score.

Conclusion

Among premenopausal breast cancer women who had undergone adjuvant chemotherapy, those who had received taxanes or tamoxifen, were overweight/obese and utilized traditional Chinese medicine had more severe menopausal symptoms. Patients who experienced worse menopausal symptoms were found to have worse breast cancer-specific QoL. Interventional studies with an aim to alleviate menopausal symptoms are warranted to assess if overall QoL of these patients could be improved.

Trial registration

Not applicable.
Literature
2.
go back to reference Yeo W, Lee HM, Chan A, Chan EYY, Chan MCM, Chan KW, et al. Risk factors and natural history of breast cancer in younger Chinese women. World J Clin Oncol. 2014;5(5):1097–106.PubMedPubMedCentralCrossRef Yeo W, Lee HM, Chan A, Chan EYY, Chan MCM, Chan KW, et al. Risk factors and natural history of breast cancer in younger Chinese women. World J Clin Oncol. 2014;5(5):1097–106.PubMedPubMedCentralCrossRef
3.
go back to reference Codacci-Pisanelli G, Del Pup L, Del Grande M, Peccatori FA. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol. 2017;113:90–6.PubMedCrossRef Codacci-Pisanelli G, Del Pup L, Del Grande M, Peccatori FA. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol. 2017;113:90–6.PubMedCrossRef
4.
go back to reference Barton DL, Ganz PA. Symptoms: menopause, infertility, and sexual health. Adv Exp Med Biol. 2015;862:115–41.PubMedCrossRef Barton DL, Ganz PA. Symptoms: menopause, infertility, and sexual health. Adv Exp Med Biol. 2015;862:115–41.PubMedCrossRef
5.
go back to reference Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Bober SL, Kereakoglow S, et al. Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer. 2014;120(15):2264–71.PubMedPubMedCentralCrossRef Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Bober SL, Kereakoglow S, et al. Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer. 2014;120(15):2264–71.PubMedPubMedCentralCrossRef
6.
go back to reference Oberguggenberger A, Meraner V, Sztankay M, Hilbert A, Hubalek M, Holzner B, Gamper E, Kemmler G, Baumgartner T, Lackinger I, Sperner-Unterweger B, Mangweth-Matzek B. Health behavior and quality of life outcome in breast Cancer survivors: prevalence rates and predictors. Clin Breast Cancer. 2018;18(1):38–44.PubMedCrossRef Oberguggenberger A, Meraner V, Sztankay M, Hilbert A, Hubalek M, Holzner B, Gamper E, Kemmler G, Baumgartner T, Lackinger I, Sperner-Unterweger B, Mangweth-Matzek B. Health behavior and quality of life outcome in breast Cancer survivors: prevalence rates and predictors. Clin Breast Cancer. 2018;18(1):38–44.PubMedCrossRef
7.
go back to reference Avis NE, Johnson A, Canzona MR, Levine BJ. Sexual functioning among early post-treatment breast cancer survivors. Support Care Cancer. 2018;26(8):2605–13.PubMedPubMedCentralCrossRef Avis NE, Johnson A, Canzona MR, Levine BJ. Sexual functioning among early post-treatment breast cancer survivors. Support Care Cancer. 2018;26(8):2605–13.PubMedPubMedCentralCrossRef
8.
go back to reference Parulekar WR, Day AG, Ottaway JA, Sheperd LE, Trudeau ME, Bramwell V, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high- risk premenopausal breast Cancer: analysis of a National Cancer Institute of Canada clinical trials group study-NCIC CTG MA. J Clin Oncol. 2005;23:6002–8.PubMedCrossRef Parulekar WR, Day AG, Ottaway JA, Sheperd LE, Trudeau ME, Bramwell V, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high- risk premenopausal breast Cancer: analysis of a National Cancer Institute of Canada clinical trials group study-NCIC CTG MA. J Clin Oncol. 2005;23:6002–8.PubMedCrossRef
9.
go back to reference Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011;29(9):1110–6.PubMedPubMedCentralCrossRef Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011;29(9):1110–6.PubMedPubMedCentralCrossRef
10.
go back to reference Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–13.PubMedCrossRef Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–13.PubMedCrossRef
11.
go back to reference Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–32.PubMedCrossRef Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–32.PubMedCrossRef
12.
go back to reference Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, et al. Analysis of chemotherapy- induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115:335–42.PubMedCrossRef Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, et al. Analysis of chemotherapy- induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115:335–42.PubMedCrossRef
13.
go back to reference Yeo W, Mo FKF, Pang E, Suen JJS, Koh J, Loong HHF, et al. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. BMC Womens Health. 2017;17(1):55.PubMedPubMedCentralCrossRef Yeo W, Mo FKF, Pang E, Suen JJS, Koh J, Loong HHF, et al. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. BMC Womens Health. 2017;17(1):55.PubMedPubMedCentralCrossRef
14.
go back to reference Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:386–405.PubMedCrossRef Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:386–405.PubMedCrossRef
15.
go back to reference Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GN. Effect of age and race on quality of life in young breast cancer survivors. Clin Breast Cancer. 2014;14(2):e21–31.PubMedCrossRef Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GN. Effect of age and race on quality of life in young breast cancer survivors. Clin Breast Cancer. 2014;14(2):e21–31.PubMedCrossRef
16.
go back to reference Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet. 1996;347(9011):1279–84.PubMedCrossRef Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet. 1996;347(9011):1279–84.PubMedCrossRef
17.
go back to reference Joly F, Espié M, Marty M, Héron JF, Henry-Amar M. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer. 2000;83(5):577–82.PubMedPubMedCentralCrossRef Joly F, Espié M, Marty M, Héron JF, Henry-Amar M. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer. 2000;83(5):577–82.PubMedPubMedCentralCrossRef
18.
go back to reference Yeo W, Mo FK, Pang E, Suen JJ, Koh J, Yip CH, Yip CC, Li L, Loong HH, Liem GS. Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy. Cancer Manag Res. 2018;10:383–9.PubMedPubMedCentralCrossRef Yeo W, Mo FK, Pang E, Suen JJ, Koh J, Yip CH, Yip CC, Li L, Loong HH, Liem GS. Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy. Cancer Manag Res. 2018;10:383–9.PubMedPubMedCentralCrossRef
19.
go back to reference Yang H, Cheng F, Wang X, Wen Z, Zhang C. On clinical application and assessment of menopause-specific quality of life (Chinese version). Chin J Epidemiol. 2005;26(1):47–51. Yang H, Cheng F, Wang X, Wen Z, Zhang C. On clinical application and assessment of menopause-specific quality of life (Chinese version). Chin J Epidemiol. 2005;26(1):47–51.
20.
go back to reference Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996;24(3):161–75.PubMedCrossRef Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996;24(3):161–75.PubMedCrossRef
21.
go back to reference Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, Wang H, Tang X. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat. 2007;106(3):413–8.PubMedCrossRef Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, Wang H, Tang X. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat. 2007;106(3):413–8.PubMedCrossRef
22.
go back to reference Brady M, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy – breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.PubMedCrossRef Brady M, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy – breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.PubMedCrossRef
24.
go back to reference Hamer J, McDonald R, Zhang L, Verma S, Leahey A, Ecclestone C, et al. Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer. 2017;25(2):409–19.PubMedCrossRef Hamer J, McDonald R, Zhang L, Verma S, Leahey A, Ecclestone C, et al. Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer. 2017;25(2):409–19.PubMedCrossRef
25.
go back to reference Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer? Menopause. 2016;23(9):1000–8.PubMedCrossRef Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer? Menopause. 2016;23(9):1000–8.PubMedCrossRef
26.
go back to reference Rosenberg SM, Partridge AH. Premature menopause in young breast cancer: effects on quality of life and treatment interventions. J Thorac Dis. 2013;5(Suppl 1):S55–61.PubMedPubMedCentral Rosenberg SM, Partridge AH. Premature menopause in young breast cancer: effects on quality of life and treatment interventions. J Thorac Dis. 2013;5(Suppl 1):S55–61.PubMedPubMedCentral
27.
go back to reference Davis SR, Panjari M, Robinson PJ, Fradkin P, Bell RJ. Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Menopause. 2014;21(10):1075–81.PubMedCrossRef Davis SR, Panjari M, Robinson PJ, Fradkin P, Bell RJ. Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Menopause. 2014;21(10):1075–81.PubMedCrossRef
28.
go back to reference Yoo C, Yun MR, Ahn JH, Jung KH, Kim HJ, Kim JE, et al. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol. 2013;72(3):565–75.PubMedCrossRef Yoo C, Yun MR, Ahn JH, Jung KH, Kim HJ, Kim JE, et al. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol. 2013;72(3):565–75.PubMedCrossRef
29.
go back to reference Lee M, Kim YH, Jeon MJ. Risk factors for negative impacts on sexual activity and function in younger breast cancer survivors. Psychooncology. 2015;24(9):1097–103.PubMedCrossRef Lee M, Kim YH, Jeon MJ. Risk factors for negative impacts on sexual activity and function in younger breast cancer survivors. Psychooncology. 2015;24(9):1097–103.PubMedCrossRef
30.
go back to reference L'Espérance S, Frenette S, Dionne A. Dionne JY; Comité de l’évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21(5):1461–74.PubMedCrossRef L'Espérance S, Frenette S, Dionne A. Dionne JY; Comité de l’évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21(5):1461–74.PubMedCrossRef
31.
go back to reference Villaseca P. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric. 2012;15(2):115–24.PubMedCrossRef Villaseca P. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric. 2012;15(2):115–24.PubMedCrossRef
32.
go back to reference Othman AH, Zaky AH. Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. Pain Med. 2014;15(3):410–7.PubMedCrossRef Othman AH, Zaky AH. Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. Pain Med. 2014;15(3):410–7.PubMedCrossRef
33.
go back to reference Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017;52:82–90.PubMedCrossRef Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017;52:82–90.PubMedCrossRef
34.
go back to reference Liem GS, Mo FK, Pang E, Suen JJ, Tang NL, Lee KM, et al. Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles. PLoS One. 2015;10(10):e0140842.PubMedPubMedCentralCrossRef Liem GS, Mo FK, Pang E, Suen JJ, Tang NL, Lee KM, et al. Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles. PLoS One. 2015;10(10):e0140842.PubMedPubMedCentralCrossRef
35.
go back to reference World Health Organisation, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific Perspective: Redefining obesity and its treatment. Sydney: Health Communications. 2000. World Health Organisation, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific Perspective: Redefining obesity and its treatment. Sydney: Health Communications. 2000.
Metadata
Title
Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors
Authors
Winnie Yeo
Elizabeth Pang
Giok S. Liem
Joyce J. S. Suen
Rita Y. W. Ng
Christopher C. H. Yip
Leung Li
Claudia H. W. Yip
Frankie K. F. Mo
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2020
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-020-1283-x

Other articles of this Issue 1/2020

Health and Quality of Life Outcomes 1/2020 Go to the issue